KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Consolidated Net Income: 2011-2024

Historic Consolidated Net Income for Sarepta Therapeutics (SRPT) over the last 14 years, with Dec 2024 value amounting to $235.0 million.

  • Sarepta Therapeutics' Consolidated Net Income fell 7028.08% to -$447.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$248.7 million, marking a year-over-year decrease of 627.64%. This contributed to the annual value of $235.0 million for FY2024, which is 143.83% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Consolidated Net Income stood at $235.0 million for FY2024, which was up 143.83% from -$536.1 million recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Consolidated Net Income registered a high of $235.0 million during FY2024, and its lowest value of -$704.1 million during FY2022.
  • For the 3-year period, Sarepta Therapeutics' Consolidated Net Income averaged around -$335.1 million, with its median value being -$536.1 million (2023).
  • In the last 5 years, Sarepta Therapeutics' Consolidated Net Income plummeted by 68.13% in 2022 and then spiked by 143.83% in 2024.
  • Over the past 5 years, Sarepta Therapeutics' Consolidated Net Income (Yearly) stood at -$554.4 million in 2020, then increased by 24.46% to -$418.8 million in 2021, then plummeted by 68.13% to -$704.1 million in 2022, then increased by 23.85% to -$536.1 million in 2023, then surged by 143.83% to $235.0 million in 2024.